Immunotherapy of Melanoma Patients

Phase 1 Completed 9 enrolled Centre Hospitalier Universitaire Vaudois

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to test whether vaccination with antigenic peptides induces an immune response in the vaccine site sentinel lymph node of patients with microscopically detectable lymph node melanoma metastases.

Timeline

Start: 1999-05
Primary completion: 2007-06
Completion: 2007-06

Publications

Results Ayyoub M, Zippelius A, Pittet MJ, Rimoldi D, Valmori D, Cerottini JC, Romero P, Lejeune F, Lienard D, Speiser DE. Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1. Clin Cancer Res. 2003 Feb;9(2):669-77.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	FluMa	Peptide	—	Other
Subject	MAGE-A10	Peptide	—	Other
Subject	Melan-A analog peptide	Peptide	—	Other
Background	Montanide adjuvant	Unknown	—	Other
Background	SB AS-2 adjuvant	Unknown	—	Other

Immunotherapy of Melanoma Patients

Summary

Timeline

Publications

Drugs

Indications